Previous 10 | Next 10 |
2023-11-09 18:24:46 ET Summary Fennec Pharmaceuticals is a commercial-stage biotech company with a single drug, PEDMARK®, which is FDA-approved to reduce the risk of hearing loss in pediatric cancer patients. The company faced challenges and delays in obtaining FDA approval b...
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.44% on the day to $6.87. Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the t...
2023-11-06 11:19:06 ET Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Conference Call November 06, 2023, 08:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rosty Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer ...
2023-11-06 06:04:04 ET More on Fennec Pharmaceuticals Fennec's Financial Concerns Overshadow Pedmark Potential (Rating Downgrade) Seeking Alpha’s Quant Rating on Fennec Pharmaceuticals Historical earnings data for Fennec Pharmaceuticals Financial infor...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Fennec Pharmaceuticals Inc. (FENC) is expected to report $-0.11 for Q3 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2023 financial results before the opening of the U.S. financia...
2023-08-18 19:24:42 ET Summary Fennec Pharmaceuticals has FDA approval for Pedmark, a drug for cisplatin-triggered ototoxicity in children, with promising prospects. Financial concerns include decreasing cash, increasing operational expenses, net loss, and potential need for addit...
2023-08-06 09:00:28 ET Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Conference Call August 3, 2023 08:30 ET Company Participants Robert Andrade - Chief Financial Officer Rostislav Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer ...
2023-08-03 13:00:53 ET Fennec Pharmaceuticals press release ( NASDAQ: FENC ): Q2 GAAP EPS of -$0.21. Net sales of $3.3M compared to $1.7M in the first quarter of 2023. Research and development expenses decreased by $1.1M for the three months ended June 30, 2023, compar...
News, Short Squeeze, Breakout and More Instantly...
Fennec Pharmaceuticals Inc. Company Name:
FENC Stock Symbol:
NASDAQ Market:
Fennec Pharmaceuticals Inc. Website:
2024-05-15 10:00:04 ET Chase Knickerbocker from Craig-Hallum issued a price target of $17.00 for FENC on 2024-05-15 08:57:00. The adjusted price target was set to $17.00. At the time of the announcement, FENC was trading at $7.34. The overall price target consensus is at...
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results. The...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 367.5% to $0.2852 on volume of 1,515,686,571 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 32.0% to $6.85 on volume of 599,135,465 shares Crown Electrokinetics Corp. (CR...